SARS-CoV-2 Lin. XBB.1.5; Omicron Var. (USA/MD-HP40900/2022) – CFHI

SARS-Related Coronavirus 2 Lineage XBB.1.5; Omicron Variant (Isolate: USA/MD-HP40900/2022) is an enveloped, positive-sense single-stranded RNA virus from the Coronaviridae family and the Betacoronaviridae genus. Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/MD HP40900/2022 was isolated from a human on November 29, 2022, in Maryland, USA. Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/MDHP40900/2022 is assigned lineage XBB.1.5 (Pango v.4.1.3 consensus call) and GISAID clade GRA using
the Phylogenetic Assignment of Named Global Outbreak lineages (PANGO) tool. The complete genome of SARS-CoV-2, isolate hCoV-19/USA/MDHP40900/2022 has been sequenced (GISAID: EPI_ISL_16026423). It was labeled as VOC Omicron GRA (B.1.1.529+BA.*), first detected in Botswana/Hong Kong/South Africa by the World
Health Organization (WHO). Each frozen aliquot contains 1 mL of heat inactivated viral culture fluid. The pre-inactivation titer was determined from an infectious aliquot. Viral inactivation is verified after heat inactivation by the absence of viral growth in tissue culture-based infectivity assays.

Heat inactivated viral culture fluids are sold as consumable testing materials. The suitability and performance characteristics should be determined by your laboratory for each intended usage. These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act or for any other product intended for administration to humans.

For BSL-2 or BSL-3 compliant labs only / -20° C.
Product Insert.pdf

Material Safety Data Sheet.pdf